|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the C allele of the -1T>C SNP of the CD40 gene (rs1883832) results in an enhanced CD40 surface abundance and pro-inflammatory phenotype of vascular endothelial cells, increasing the susceptibility to atherosclerosis and CHD in humans.This appears to be compensated by an enhanced shedding of sCD40 from the endothelial cell membrane to neutralize excess CD40 ligand. sCD40 might be a potential new biomarker for the pro-inflammatory processes occurring in atherosclerosis.
|
31373353 |
2019 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Disrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune suppression.
|
29406859 |
2018 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors.
|
28883908 |
2017 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The relationship between soluble CD40 ligand level and atherosclerosis in white-coat hypertension.
|
29162926 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85+/-1.25 microg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74+/-1.47 microg/l), CD40 ligand (before lipoprotein apheresis: 6498+/-2529 ng/l, after lipoprotein apheresis: 4057+/-2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7+/-1.1 nmol/l, after lipoprotein apheresis: 5.5+/-1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy.
|
28379034 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Indeed, blockade of CD40L by neutralizing antibodies or genetic disruption in mice prevents atherosclerosis and atherothrombosis.
|
26719354 |
2017 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Platelet cluster of differentiation 40 (CD40) ligand (CD40L and CD154) plays a key role in mediating platelet-induced inflammation in atherosclerosis.
|
26821950 |
2016 |
|
Atherosclerosis
|
0.300 |
Therapeutic
|
disease |
RGD |
Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model.
|
26261622 |
2015 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A role for platelet CD40L in mediating thrombotic and inflammatory processes in atherosclerosis has also been reported.
|
24030045 |
2014 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Costimulatory cascades such as the CD40L-CD40 dyad enhance immune cell activation and inflammation during atherosclerosis.
|
24664276 |
2014 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The CD40/CD40L dyad is deemed to play a central role in several inflammatory processes, including atherosclerosis.
|
23896727 |
2013 |
|
Atherosclerosis
|
0.300 |
Therapeutic
|
disease |
RGD |
Regression analysis revealed that the predictor of atherosclerosis was CD40L.
|
23984971 |
2013 |
|
Atherosclerosis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.
|
23166616 |
2012 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specific inhibition of CD40L-Mac-1 binding may represent an attractive anti-inflammatory treatment strategy for atherosclerosis and other inflammatory conditions, potentially avoiding the unwanted immunologic and thrombotic effects of global inhibition of CD40L.
|
21998326 |
2011 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ligands of this family comprise multiple important cytokines such as TNFα, CD40L, and interleukin-1β that promote chronic inflammatory diseases such as atherosclerosis.
|
20651286 |
2010 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the role of CD40L in pro-inflammatory gene expression and cellular differentiation in adipose tissue to obtain insight into mechanisms linking the MS with atherosclerosis.
|
20174757 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
1.CD40 and CD40 ligand (CD40L) have a critical role in the pathophysiology and risk prediction of coronary artery syndrome, including atherothrombosis and atherosclerosis.
|
20456428 |
2010 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The interaction between CD40 and its ligand (CD40L) has been implicated in the pathogenesis of atherosclerosis and is recognized as a central event in the development of immuno-inflammatory processes.
|
19187784 |
2009 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we illustrate the various functional features of these molecules, while describing the increasingly important role of CD40 in CD154-associated vascular pathologies such as atherosclerosis and atherothrombosis.
|
19282242 |
2009 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
A role for CD40-CD40L interactions has been identified in atherosclerosis, and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors.
|
18977174 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
LHGDN |
Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.
|
18787388 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Costimulatory molecules of the tumor necrosis factor superfamily such as CD40/CD40L and OX40/OX40L have been implicated in atherosclerosis.
|
18285570 |
2008 |
|
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The CD40 receptor and its ligand (CD40L) are known to modulate both inflammation and thrombosis-2 processes important for the development and clinical expression of atherosclerosis.
|
19061720 |
2008 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Strong evidence supports a role for CD40 ligand (CD40L) as marker and mediator of inflammatory diseases such as atherosclerosis.
|
17372166 |
2007 |
|
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
LHGDN |
The expression and potential role of platelet membrane CD154 and sCD154 in atherosclerosis was investigated in patients with peripheral arterial disease.
|
16777115 |
2007 |